Scribd Logo
Upload

Welcome to Scribd!

  • Procos New Generic List - 2014 - V5 - September 2014

    Uploaded by

    amin138ir
    52 views1 page
    This document provides information about PROCOS S.p.A., an Italian pharmaceutical company, and their portfolio of validated and developing drug products. It lists several APIs that have been validated for various therapeutic indications in both the EU and US markets. Several other APIs are listed as still under development or evaluation, including their therapeutic class and stage of research. The document concludes with a disclaimer and date.

    Original Description:

    Procos New Generic APIS

    Original Title

    Procos New Generic List_2014_V5_September 2014

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This document provides information about PROCOS S.p.A., an Italian pharmaceutical company, and their portfolio of validated and developing drug products. It lists several APIs that have been validated for various therapeutic indications in both the EU and US markets. Several other APIs are listed as still under development or evaluation, including their therapeutic class and stage of research. The document concludes with a disclaimer and date.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    52 views1 page

    Procos New Generic List - 2014 - V5 - September 2014

    Uploaded by

    amin138ir
    This document provides information about PROCOS S.p.A., an Italian pharmaceutical company, and their portfolio of validated and developing drug products. It lists several APIs that have been validated for various therapeutic indications in both the EU and US markets. Several other APIs are listed as still under development or evaluation, including their therapeutic class and stage of research. The document concludes with a disclaimer and date.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    PROCOS S.p.A.

    Via Matteotti n. 249 - 28062 CAMERI (NO) ITALY


    Phone: ++39-0321-642211 - Fax: ++39-0321-642219
    E-mail: procos@procos.it
    www.procos.it

    NEW PRODUCTS
    VALIDATED
    API

    Fampridine/Dalfampridine

    CLASS/INDICATION

    Treatment of some symptoms of Multiple Sclerosis

    Guanfacine

    Antihypertensive and Treatment of ADHD

    Iloperidone

    Antipsychotic

    Landiolol

    Antiarrhythmic

    Lurasidone

    Antipsychotic

    Naftopidil

    Antihypertensive (Treatment of BPH)

    Ranolazine

    Antianginal

    Sivelestat

    Acute Respiratory Failure

    DMF

    EU: filed
    US: available for reference
    EU: filed
    US: filed
    EU: filed
    US: available for reference
    EU: filed
    JP: filed
    EU: filed
    US: in progress
    EU: filed
    JP: filed
    EU: filed
    US: in progress
    EU: filed
    JP: filed

    UNDER DEVELOPMENT
    API

    Amifampridine
    Roflumilast
    Silodosin
    Agomelatine
    Minodronic Acid

    CLASS/INDICATION

    Treatment of Lambert-Eaton syndrome (LEMS)


    Antiasthmatic (COPD)
    Treatment of BPH
    Antidepressant
    Anti-osteoporosis

    DEVELOPMENT STATUS

    LAB
    LAB
    KILOLAB
    PILOT
    INDUSTRIAL

    UNDER EVALUATION
    API
    Alogliptin
    Apixaban
    Avanafil
    Dapagliflozin
    Dolutegravir
    Droxidopa
    Efinaconazole
    Levomilnacipran
    Macitentan
    Miltefosine
    Perampanel
    Riociguat
    Simeprevir
    Sofosbuvir
    Vortioxetine

    CLASS/INDICATION
    Antidiabetic
    Antithrombotic
    Erectyle disfunction
    Antidiabetic
    HIV
    Neurogenic orthostatic hypotension
    Onychomycosis
    Major depressive disorder (MDD)
    Pulmonary Arterial Hypertension (PAH)
    Leishmaniasis
    Antiepileptic
    Pulmonary Arterial Hypertension (PAH)
    Hepatitis C
    Hepatitis C
    Depressive Disorder

    STATUS

    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening
    Screening

    This list is not to be construed as a non-infringement or as an offer to sell in those countries where such would
    constitute an infringement of third parties patent rights.
    September 2014

    You might also like